

Journal of Visualized Experiments

Fabricating a Kidney Cortex Extracellular Matrix-Derived Hydrogel

--Manuscript Draft--

Article Type:	Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58314R2
Full Title:	Fabricating a Kidney Cortex Extracellular Matrix-Derived Hydrogel
Keywords:	bioengineering; Tissue Engineering; extracellular matrix; hydrogel; kidney; endothelial cells
Corresponding Author:	Ying Zheng, Ph.D. University of Washington Seattle, Washington UNITED STATES
Corresponding Author's Institution:	University of Washington
Corresponding Author E-Mail:	yingzy@uw.edu
Order of Authors:	Harrison Lee Hiraki Ryan Nagao Johnathan Himmelfarb Ying Zheng, Ph.D.
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	420 Brotman Bldg., 850 Republican St., Seattle, WA, 98109

TITLE:

Fabricating a Kidney Cortex Extracellular Matrix-Derived Hydrogel

AUTHORS & AFFILIATIONS:

Harrison L Hiraki¹, Ryan J Nagao², Jonathan Himmelfarb³, Ying Zheng²

¹Department of Bioengineering, University of Washington, Seattle, WA, USA

²Department of Bioengineering, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA

³Department of Medicine, Kidney Research Institute, University of Washington, Seattle, WA, USA

Corresponding Authors:

Jonathan Himmelfarb (himmej@uw.edu)

Ying Zheng (yingzy@uw.edu)

Email Addresses of Co-Authors:

Harrison L Hiraki (hirakih@uw.edu)

Ryan J Nagao (nagao@uw.edu)

KEYWORDS:

Bioengineering, tissue engineering, extracellular matrix, hydrogel, kidney, endothelial cells

SUMMARY:

Here we present a protocol to fabricate a kidney cortex extracellular matrix-derived hydrogel to retain the native kidney extracellular matrix (ECM) structural and biochemical composition. The fabrication process and its applications are described. Finally, a perspective on using this hydrogel to support kidney-specific cellular and tissue regeneration and bioengineering is discussed.

ABSTRACT:

Extracellular matrix (ECM) provides important biophysical and biochemical cues to maintain tissue homeostasis. Current synthetic hydrogels offer robust mechanical support for *in vitro* cell culture but lack the necessary protein and ligand composition to elicit physiological behavior from cells. This manuscript describes a fabrication method for a kidney cortex ECM-derived hydrogel with proper mechanical robustness and supportive biochemical composition. The hydrogel is fabricated by mechanically homogenizing and solubilizing decellularized human kidney cortex ECM. The matrix preserves native kidney cortex ECM protein ratios while also enabling gelation to physiological mechanical stiffnesses. The hydrogel serves as a substrate upon which kidney cortex-derived cells can be maintained under physiological conditions. Furthermore, the hydrogel composition can be manipulated to model a diseased environment which enables the future study of kidney diseases.

INTRODUCTION:

Extracellular matrix (ECM) provides important biophysical and biochemical cues to maintain tissue homeostasis. The complex molecular composition regulates both structural and functional

properties of tissue. Structural proteins provide cells with spatial awareness and allow for adhesion and migration¹. Bound ligands interact with cell surface receptors to control cell behavior². Kidney ECM contains a plethora of molecules whose composition and structure varies depending on anatomical location, developmental stage, and disease state^{3,4}. Recapitulating the complexity of ECM is a key aspect in studying kidney-derived cells *in vitro*.

Previous attempts at replicating ECM microenvironments have focused on decellularizing whole tissue to create scaffolds capable of recellularization. Decellularization has been performed with chemical detergents such as sodium dodecyl sulfate (SDS) or non-ionic detergents, and it utilizes either whole organ perfusion or immersion and agitation methods⁵⁻¹³. The scaffolds presented here preserve the structural and biochemical cues found in native tissue ECM; furthermore, recellularization with donor-specific cells has clinical relevance in reconstructive surgery¹⁴⁻¹⁹. However, these scaffolds lack structural flexibility and are therefore incompatible with many current devices used for *in vitro* studies. To overcome this limitation, many groups have further processed decellularized ECM into hydrogels²⁰⁻²⁴. These hydrogels are compatible with injection molding and bioink and circumvent micrometer scale spatial constraints that decellularized scaffolds place on cells. Furthermore, molecular composition and ratios found in native ECM are preserved^{3,25}. Here we demonstrate a method to fabricate a hydrogel derived from kidney cortex ECM (kECM).

The purpose of this protocol is to produce a hydrogel that replicates the microenvironment of the kidney cortical region. Kidney cortex tissue is decellularized in a 1% SDS solution under constant agitation to remove cellular matter. SDS is commonly used to decellularize tissue because of its ability to quickly remove immunological cellular material^{6,7,9,26}. The kECM is then subject to mechanical homogenization and lyophilization^{5,6,9,11,26}. Solubilization in a strong acid with pepsin results in a final hydrogel stock solution^{20,27}. Native kECM proteins that are important for structural support and signal transduction are preserved^{3,25}. The hydrogel can also be gelled to within one order of magnitude of native human kidney cortex²⁸⁻³⁰. This matrix provides a physiological environment that has been used to maintain the quiescence of kidney-specific cells compared to hydrogels from other matrix proteins. Furthermore, matrix composition can be manipulated, for example, through the addition of collagen-I, to model disease environments for the study of renal fibrosis and other kidney diseases^{31,32}.

PROTOCOL:

Human kidneys were isolated by LifeCenter Northwest following ethical guidelines set by the Association of Organ Procurement Organizations. This protocol follows animal care and cell culture guidelines outlined by the University of Washington.

1. Preparation of Human Kidney Tissue

1.1. Preparation of decellularization solution

1.1.1. Sterilize a 5000 mL beaker and a 70 x 10 mm stir bar.

1.1.2. Mix 1:1000 (weight:volume) sodium dodecyl sulfate (SDS) in autoclaved deionized water in the beaker. Leave the solution on a stir plate at approximately 200 rpm for 24 h or until the SDS is completely dissolved.

Note: Typically, 2500 mL of 1% SDS solution is sufficient to decellularize a single human kidney.

1.1.3. Transfer the solution to a 500 mL sterile vacuum filter and filter it into sterilized sealable containers.

1.2. Processing of kidney tissue

1.2.1. Wash and autoclave a pair of forceps, two hemostat clamps, a pair of general service grade scissors, two scalpel blade handles, a 1000 mL beaker covered with aluminum foil, and a 36 x 9 mm stir bar.

1.2.2. Line a tissue culture hood with underpad. Place the beaker, a sterile tissue culture dish (150 x 25 mm), and the whole kidney organ into the hood. Fill the beaker with 500 mL of 1% SDS solution.

Note: Human kidneys were received on ice from LifeCenter NorthWest.

1.2.3. Place the kidney in the sterile tissue culture dish (**Figure 1A**). Remove all perirenal fat by lightly shaving around the renal capsule with a scalpel (**Figure 1B**).

1.2.4. Make a shallow 8-10 cm incision with the scalpel, just deep enough to break open the renal capsule without damaging the underlying cortex tissue, across the superior end of the kidney. Remove the renal capsule by peeling it away from the cortex tissue with two hemostat clamps (**Figure 1C**).

1.2.5. Bisect the kidney along the coronal plane by using the scalpel along the lateral side of the kidney (**Figure 1D**). Isolate cortex tissue from both halves by carving out the medullar region with the scalpel (**Figure 1E**) and dice the cortex tissue into 0.5 cm³ pieces (**Figure 1F**). Remove any large visible vessels.

1.3. Isolation of extracellular matrix

1.3.1. In a tissue culture hood, fill a 1000 mL beaker with 500 mL of 1% SDS solution. Place the diced cortex tissue and stir bar into the beaker containing SDS solution. Cover the beaker with autoclaved aluminum foil and place it on a stir plate at approximately 400 rpm outside of the tissue culture hood.

1.3.2. After the cortex tissue has been on the stir plate for 24 h, bring the beaker into a tissue culture hood and add a 40 µm sterile cell strainer made with nylon mesh. Fill a separate 1000 mL beaker with 200 mL of bleach and place it in the tissue culture hood.

1.3.2. Pipette out the SDS solution through the cell strainer into the beaker containing bleach. Pipette out all SDS solution until only decellularized tissue and the cell strainer remain in the beaker.

Note: The cell strainer should prevent any tissue from being removed during solution aspiration.

1.3.3. Leave the cell strainer in the beaker and fill with 500 mL of fresh SDS solution. Cover the beaker with the same aluminum foil and place onto a stir plate at the same speed as before.

1.3.4. Repeat steps 1.3.1-1.3.3 every 24 hours with fresh SDS solution for a total of five days.

1.3.5. Rinse decellularized tissue with autoclaved DI water every 24 h for 3 days total, following the technique outlined in steps 1.3.1-1.3.3.

1.3.6. Rinse decellularized tissue with cell culture grade water every 24 h for 2 days total, following the technique outlined in steps 1.3.1-1.3.3.

1.3.7. Repeat steps 1.3.1-1.3.2. Transfer the decellularized tissue (referred to as kECM from this point on) into a 30 mL self-standing conical tube and fill it with cell culture grade water until all the tissue is submerged.

2. **Fabrication of Hydrogel Stock Solution**

2.1. **Mechanical processing of decellularized tissue**

2.1.1. In a tissue culture hood, mechanically homogenize the kECM within the conical tube with a tissue homogenizer for 2 min.

Note: Homogenized kECM should resemble an opaque solution with no visible pieces of ECM.

2.1.2. Submerge the conical tube containing the kECM in liquid nitrogen until boiling surrounding the tube no longer persists. Store the kECM at -4 °C overnight.

2.2. **Lyophilization of frozen decellularized tissue**

2.2.1. Slightly loosen the conical tube cap to allow for gas exchange and place the tube into a lyophilization machine. Lyophilize the kECM for three days or until it resembles a fine white powder. Store at -4 °C.

2.3. **Chemical digestion and solubilization of gel**

2.3.1. Autoclave a 20 mL scintillation vial and cap, a 15.9 x 7.9 mm stir bar, and one pair of fine-tip forceps.

2.3.2. Weigh the lyophilized kECM and calculate the volume of HCl and mass of pepsin needed to solubilize the kECM to a 3% (30 mg/mL) solution using the following equations, where m_{pepsin} is the mass of pepsin, m_{tissue} is the mass of lyophilized tissue, and V_{HCl} is the volume of 0.01 N HCl:

$$m_{pepsin}(mg) = \frac{m_{tissue}(mg)}{10}$$

$$V_{HCl}(mL) = \frac{m_{tissue}(mg)}{30(\frac{mg}{mL})}$$

2.3.3. In a tissue culture hood, add porcine gastric pepsin, 0.01 N HCl, and the stir bar to the scintillation vial, and leave it on a stir plate at approximately 500 rpm until all the pepsin has dissolved. Transfer the lyophilized kECM to the scintillation vial and leave the solution on a stir plate at approximately 500 rpm for three days.

3. Hydrogel Gelation

3.1 Kidney ECM hydrogel preparation

3.1.1. Gel the hydrogel by mixing the kECM hydrogel stock solution with 1 N NaOH, 10x Media Supplement (M199), and cell culture media. Keep all the solutions on ice.

Note: Final gel concentrations of 7.5 mg/mL were used for cell culture. 1 mL of kECM gel was sufficient for cell culture experiments presented.

3.1.1.2. Determine the volume of workable kECM gel produced and volume of stock kECM hydrogel needed by using the following equation, where V_{final} is the volume of gel created, $V_{stock\ kECM}$ is the volume of stock kECM hydrogel needed, $C_{stock\ kECM}$ is the concentration of the stock kECM hydrogel, and C_{final} is the concentration of the final gel:

$$V_{stock\ kECM} = \frac{V_{final} * C_{final}}{C_{stock\ kECM}}$$

3.1.1.3. Determine the volume of neutralizing reagents needed by using the following equations, where V_{NaOH} is the volume of 1 N NaOH, V_{10X} is the volume of M199 10X media supplement, and V_{1X} is the volume of cell culture media:

$$V_{NaOH} = 0.022 * V_{stock\ kECM}$$

$$V_{10X} = 0.1 * V_{stock\ kECM}$$

$$V_{1X} = V_{final} - V_{stock\ kECM} - V_{NaOH} - V_{10X}$$

3.1.1.4. In a tissue culture hood, pipette the neutralizing reagents (NaOH, M199, and cell culture media) into a sterile 30 mL self-standing conical tube. Mix the neutralizing reagent solution with a microspatula.

3.1.1.5. Use a sterile 1 mL syringe to transfer the appropriate volume of stock kECM hydrogel to the neutralizing reagent solution. Use a microspatula to gently mix the solution until a homogeneous in color hydrogel solution is obtained.

Note: Avoid introducing air bubbles by stirring slowly and gently.

3.1.1.6. To incorporate cells into the kECM hydrogel, subtract 10 μ L of cell culture media (V_{IX}) from the neutralizing solution volume calculations in step 3.1.1.3.

3.1.1.6.1. Suspend cells into 10 μ L of cell culture media. Determine the number of cells to be suspended by using the following equation, where $\#_{cells}$ implies the number of cells to suspend and V_{final} is the volume of gel created:

$$\#_{cells} = 300,000 \left(\frac{cells}{mL} \right) * V_{final}(mL)$$

Note: 300,000 cells/mL is the concentration of cells used in the kECM gel.

3.1.1.6.2. Pipette the 10 μ L of cell suspended solution into the final kECM gel after the kECM stock solution has been mixed with neutralizing reagent solution. Stir the solution with a microspatula until the cells are evenly distributed.

3.1.2. Use a 1 mL syringe to fill a desired cell culture device with the kECM hydrogel.

3.1.3. Allow the gel to set at 37 $^{\circ}$ C for 1 h before transferring or plating cells.

REPRESENTATIVE RESULTS:

The kECM hydrogel provides a matrix for kidney cell culture with similar chemical composition as the native kidney microenvironment. To fabricate the hydrogel, kidney cortex tissue is mechanically isolated from a whole kidney organ and diced (**Figure 1**). Decellularization with a chemical detergent (**Figures 2A.1-A.3**) followed by rinses with water to remove detergent particles (**Figures 2A.4-A.6**) yields isolated kidney cortex ECM. Histological evaluation confirms typical basal laminar proteins such as collagen-IV and laminin and structural proteins such as collagen-I are preserved, with vitronectin as the only noted exception (**Figure 2B**). Furthermore, protein composition, including preservation of isoforms, in the ECM remains consistent with observed values in native kidney ECM (**Figure 3**). The ECM (**Figure 4A**) is mechanically homogenized and lyophilized (**Figure 4B**) then solubilized to produce the final kECM hydrogel (**Figure 4C**). The kECM hydrogel appeared opaque with small amounts of visible tissue and was not as viscous as traditional collagen-I hydrogel. Rheological measurement of gelled kECM at a

concentration of 15 mg/mL revealed a complex modulus (dynamic elastic modulus) of around 800 Pa over the linear range of strain values, significantly greater than that of 7.5 mg/mL collagen-I ($p = 1.602E-14$). Human kidney peritubular microvascular endothelial cells (HKMECs) cultured on collagen-I, kECM, and a 1:1 mixture gel showed differences in phenotype, specifically in CD31 expression around cell surfaces and junctions (**Figure 5**). HKMECs cultured on collagen-I displayed uniform CD31 expression while HKMECs cultured on the two gels containing kECM displayed reduced CD31 expression in uneven distributions. Matrix type did not appear to affect the high PV1 and low VWF expression in the HKMECs.

FIGURE AND TABLE LEGENDS:

Figure 1: Isolation of kidney cortex tissue. Mechanical processing of a whole kidney organ to isolate the cortex tissue as a base material for the kECM hydrogel. Mechanical isolation begins with (A) the removal of the perirenal adipose tissue. Large pieces of adipose tissue can be torn away from the kidney with hemostat clamps. Remaining pieces of adipose tissue can be removed by running a scalpel against the renal capsule at an angle. (B) The renal capsule is best removed by making a shallow incision along the superior end of the kidney and (C) peeling the renal capsule away from the underlying tissue with hemostat clamps. (D) Bisecting the kidney along the coronal axis allows for the visualization of the cortex and medulla regions. (E) Isolation of the cortex tissue is best done by carving out pieces of the medulla tissue with a scalpel. The color of the cortical region is noticeably darker than that of the medullar region and can be used to differentiate the two anatomically distinct tissues. Final processing of the cortex tissue involves (F) dicing the tissue into 0.5 cm^3 pieces to aid in subsequent decellularization.

Figure 2: Decellularization of cortex tissue. Visual and histological characterization of decellularized tissue. (A.1) Submerging diced cortex tissue in 1% SDS solution causes lysing of cells and removal of cellular material. After (A.2) 1 h and (A.3) 24 h, the tissue begins to lose color, indicating cellular matter is being removed. By (A.4) 120 h the tissue is blanched and only the ECM remains. Rinses with water at (A.5) 24 h and (A.6) 120 h show no visible changes to the tissue. (B) Immunofluorescence staining of untreated and decellularized cortex tissue reveals near complete removal of cellular matter and preservation of major structural proteins (collagen-IV = Col-IV; laminin = LAM; fibronectin = FN; heparin sulfate proteoglycans = HSPG; and vitronectin = VN). Scale = $100\text{ }\mu\text{m}$.

Figure 3: Mass spectroscopy of decellularized tissue. Analysis of decellularized cortex tissue by mass spectrometry to determine ECM protein composition. All ratios are measured as mass percent. (A) Structural and other proteins associated with the basal lamina were present with collagen-IV and -I being the most highly represented. (B.1) Collagen-IV A1 and A2 chains, ubiquitous in all basement membranes, were conserved. Collagen-IV A3 and A5 chains, present only in basement membranes of the glomerulus, were also detected. (B.2) Common isoforms of laminins and (B.3) collagen-I were also detected. This figure was reproduced with permission¹².

Figure 4: Fabrication of kECM hydrogel. Mechanical and chemical processing of decellularized cortex tissue yields a workable kECM hydrogel with sufficient mechanical properties following gelation with neutralizing reagents. (A) Decellularized cortex tissue is mechanically homogenized

with a tissue homogenizer until no visible pieces of ECM remain. (B) A coarse powder was yielded after 3 days under lyophilization. (C) Solubilization in HCl and chemical digestion with pepsin in a scintillation vial resulted in a workable kECM hydrogel. The hydrogel was opaque and of a low viscosity. (D) Physical characterization of the kECM hydrogel following gelation with neutralizing reagents. Rheological experiments were performed with a 30 mm diameter parallel plate system. The sample edges were protected with mineral oil and the loading platform was set at 37 °C. The kECM hydrogel was allowed to gel for 1 h prior to testing. Viscoelastic properties of the gel were measured with a strain sweep between 0.01 to 20%. Three samples of both kECM and collagen-I were tested (n = 3).

Figure 5: Cell growth characterization. Characterization of morphological differences in HKMECs grown on different matrices. Hydrogels were mixed with neutralizing reagents and set at 37 °C for 45 min in open-faced polydimethylsiloxane molds. HKMECs were seeded on the surface of the gels and kept in culture for 72 h before being fixed and stained. Immunofluorescent images of HKMECs cultured in (A and D) 7.5 mg/mL collagen-I gel; (B and E) 7.5 mg/mL kECM gel; and (C and F) 7.5 mg/mL 1:1 mixture gel. (A–C): red = CD31; green = VWF; blue = nuclei; scale bar = 50 µm. (D–F): red = F-actin; green = PV1; blue = nuclei; scale bar = 50 µm. This figure was reproduced with permission¹².

DISCUSSION:

Matrices provide important mechanical and chemical cues that govern cell behavior. Synthetic hydrogels are able to support complex 3-dimensional patterning but fail to provide the diverse extracellular cues found in physiological matrix microenvironments. Hydrogels derived from native ECM are ideal materials for both *in vivo* and *in vitro* studies. Previous studies have used decellularized ECM hydrogels to coat synthetic biomaterials to prevent host immunological responses^{33,34}, to differentiate stem cells³⁵⁻³⁸, as a substrate for 2D and soft lithography cell culture³⁹⁻⁴², and in preparation of bioinks for 3-dimensional printing⁴³⁻⁴⁶. ECM hydrogels provide cells with proper signaling to initiate adhesion and control further proliferation and differentiation^{2,47}.

The ratios and composition of major components of the ECM, such as collagens, laminins, elastin, fibronectin, and glycosaminoglycans, are highly dependent on the anatomical location and functionality of the tissue⁴⁸⁻⁵⁰. It is well established that using nonspecific or nonnative ECM-derived hydrogels will elicit improper responses from cells^{21,51-54}. In the kidney, ECM composition varies widely between anatomical locations^{1,2}. It is, therefore, important to differentiate between regions such as the cortex, medulla, or papilla before fabricating hydrogels for experimental use.

The kECM matrix fabricated here preserves native kidney cortex ECM protein ratios following decellularization while also enabling gelation to a physiologically relevant mechanical stiffness^{3,25,28-30}. Serum albumin, a blood plasma protein, was detected in trace amounts within the decellularized cortex tissue, possibly due to binding to heparin that escaped decellularization and rinsing^{55,56}. Although pepsin, a non-native chemical to kidney cortex ECM, is present in the stock kECM solution, it only accounts for 2.5% (w/v) of the final gelled product. Furthermore,

pepsin becomes deactivated with the addition of the neutralizing reagent solution⁵⁷.

The kECM hydrogel serves as a substrate upon which kidney cortex-specific cells can be maintained under physiological conditions. We demonstrated that this matrix can support HKMEC growth on a planar surface. These HKMECs maintained a quiescent physiological state as determined through functional assays, phenotypic expression, and genetic expression⁵⁸. In contrast, these cells became activated when collagen-I, a matrix component correlated with kidney fibrosis, was added to the kECM hydrogel at a 1:1 ratio⁵⁹. By comparison, when human umbilical vein endothelial cells were cultured on collagen-I, they were quiescent, and when mixed with kECM they became activated¹². Accordingly, collagen-I is known to be an integral component of the basement membrane composition within the umbilical cord and is decreased under pathological states such as preeclampsia^{38,60}. These results highlight the importance of providing cells with tissue-specific cues to maintain quiescence and also how manipulation of the ECM milieu can affect homeostasis.

Whereas all steps in the outlined procedure are important, several steps are critical in ensuring the viability of the fabricated hydrogel. The degree of homogenization of the decellularized cortex tissue will vary based on the technique or equipment used. It is important to find a technique that will best homogenize the tissue. During solubilization, the pH should be kept at 3-4 to ensure the pepsin is active. When mixing the hydrogel with neutralizing reagents, the gel must be mixed thoroughly and without the introduction of air bubbles. If a uniform mixture is difficult to obtain, check the pH of the gel solution to ensure it is neutral.

The representative results presented in this method demonstrate how a physiologically relevant matrix for the *in vitro* study of kidney cells can be achieved. Decellularized kidney cortex ECM provides an ideal base material to support kidney-derived cell growth as ECM protein ratios are conserved in the final hydrogel product^{3,25}. The gelled product can also achieve physiologically relevant mechanical properties²⁸⁻³⁰. The kECM hydrogel allows for proper cell-matrix interactions and has been shown to elicit greater physiological behavior from kidney cells than collagen-I when cultured on a planar surface. Furthermore, the hydrogel can be seeded with kidney-specific cells prior to gelation to model a more physiologically relevant 3-dimensional environment. The composition of the kECM hydrogel can also be easily manipulated. For example, mixing the hydrogel with varying amounts of collagen-I prior to gelation could produce matrices that mimic progressive states of renal fibrosis^{31,32}. The tunability of this ECM-derived hydrogel to mimic known diseased ECM compositions warrants further investigation and will enable the future study of kidney diseases.

ACKNOWLEDGMENTS:

The authors would like to acknowledge the Lynn and Mike Garvey Imaging Laboratory at the Institute for Stem Cell and Regenerative Medicine and LifeCenter NorthWest. They would also like to acknowledge the financial support of National Institutes of Health grants, UH2/UH3 TR000504 (to J.H.) and DP2DK102258 (to Y.Z.), NIH T32 training grant DK0007467 (to R.J.N.), and an unrestricted gift from the Northwest Kidney Centers to the Kidney Research Institute.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

1. Lelongt, B., Ronco, P. Role of extracellular matrix in kidney development and repair. *Pediatric Nephrology*. **18** (8), 731–742 (2003).
2. Yue, B. Biology of the Extracellular Matrix: An Overview. *Journal of Glaucoma*. **23**, S20-S23 (2014).
3. Miner, J. H. Renal basement membrane components. *Kidney International*. **56** (6), 2016–2024 (1999).
4. Petrosyan, A., *et al.* Decellularized Renal Matrix and Regenerative Medicine of the Kidney: A Different Point of View. *Tissue Engineering Part B*. **22** (3), 183-192 (2016).
5. Caralt, M., *et al.* Optimization and Critical Evaluation of Decellularization Strategies to Develop Renal Extracellular Matrix Scaffolds as Biological Templates for Organ Engineering and Transplantation. *American Journal of Transplantation*. **15** (1), 64–75 (2015).
6. Nakayama, K. H., Batchelder, C. A., Lee, C. I., Tarantal, A. F. Decellularized rhesus monkey kidney as a three-dimensional scaffold for renal tissue engineering. *Tissue Engineering Part A*. **16** (7), 2207–2216 (2010).
7. Nakayama, K. H., Lee, C. C. I., Batchelder, C. A., Tarantal, A. F. Tissue Specificity of Decellularized Rhesus Monkey Kidney and Lung Scaffolds. *Public Library of Science ONE*. **8** (5), e64134 (2013).
8. Orlando, G., *et al.* Production and implantation of renal extracellular matrix scaffolds from porcine kidneys as a platform for renal bioengineering investigations. *Annals of Surgery*. **256** (2), 363–370 (2012).
9. Sullivan, D. C., *et al.* Decellularization methods of porcine kidneys for whole organ engineering using a high-throughput system. *Biomaterials*. **33** (31), 7756–7764 (2012).
10. Choi, S. H., *et al.* Development of a porcine renal extracellular matrix scaffold as a platform for kidney regeneration. *Journal of Biomedical Materials Research Part A*. **103** (4), 1391–1403 (2015).
11. Ross, E. A., *et al.* Mouse stem cells seeded into decellularized rat kidney scaffolds endothelialize and remodel basement membranes. *Organogenesis*. **8** (2), 49–55 (2012).
12. Nagao, R. J., *et al.* Decellularized Human Kidney Cortex Hydrogels Enhance Kidney Microvascular Endothelial Cell Maturation and Quiescence. *Tissue Engineering Part A*. **22** (19-20), 1140–1150 (2016).
13. Gupta, S. K., Mishra, N. C., Dhasmana, A. Decellularization Methods for Scaffold Fabrication. *Methods in Molecular Biology* 1–10 (2017).
14. Hudson, T., *et al.* Optimized Acellular Nerve Graft is Immunologically Tolerated and Supports Regeneration. *Tissue Engineering*. **10** (11), 1641–1651 (2004).
15. Atala, A., Bauer, S. B., Soker, S., Yoo, J. J., Retik, A. B. Tissue-engineered autologous bladders for patients needing cystoplasty. *Lancet*. **367** (9518), 1241–1246 (2006).
16. Ott, H. C., *et al.* Perfusion-decellularized matrix: using nature’s platform to engineer a bioartificial heart. *Nature Medicine*. **14** (2), 213–221 (2008).
17. Uygun, B., *et al.* Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. *Nature Medicine*. **16** (7), 814–820

- (2010).
18. Nagao, R. J., *et al.* Preservation of Capillary-beds in Rat Lung Tissue Using Optimized Chemical Decellularization. *Journal of Materials Chemistry B*. **1** (37), 4801–4808 (2013).
19. Song, J. J., *et al.* Regeneration and experimental orthotopic transplantation of a bioengineered kidney. *Nature Medicine*. **19** (5), 646–651 (2013).
20. Freytes, D. O., Martin, J., Velankar, S. S., Lee, A. S., Badylak, S. F. Preparation and rheological characterization of a gel form of the porcine urinary bladder matrix. *Biomaterials*. **29** (11), 1630–1637 (2008).
21. Wolf, M. T., *et al.* A hydrogel derived from decellularized dermal extracellular matrix. *Biomaterials*. **33** (29), 7028–7038 (2012).
22. Fisher, M. B., *et al.* Potential of healing a transected anterior cruciate ligament with genetically modified extracellular matrix bioscaffolds in a goat model. *Knee Surgery, Sports Traumatology, Arthroscopy*. **20** (7), 1357–1365 (2012).
23. Ghuman, H., *et al.* ECM hydrogel for the treatment of stroke: Characterization of the host cell infiltrate. *Biomaterials*. **91**, 166–181 (2016).
24. Rijal, G. The decellularized extracellular matrix in regenerative medicine. *Regenerative Medicine*. **12** (5), 475–477 (2017).
25. Lennon, R., *et al.* Global Analysis Reveals the Complexity of the Human Glomerular Extracellular Matrix. *Journal of the American Society of Nephrology*. **25** (5), 939–951 (2014).
26. Bonandrini, B., *et al.* Recellularization of Well-Preserved Acellular Kidney Scaffold Using Embryonic Stem Cells. *Tissue Engineering Part A*. **20** (9-10), 1486–1498 (2014).
27. O'Neill, J. D., Freytes, D. O., Anandappa, A. J., Oliver, J. A., Vunjak-Novakovic, G. V. The regulation of growth and metabolism of kidney stem cells with regional specificity using extracellular matrix derived from kidney. *Biomaterials*. **34** (38), 9830–9841 (2013).
28. Streitberger, K.-J., *et al.* High-resolution mechanical imaging of the kidney. *Journal of Biomechanics*. **47** (3), 639–644 (2014).
29. Bensamoun, S. F., *et al.* Stiffness imaging of the kidney and adjacent abdominal tissues measured simultaneously using magnetic resonance elastography. *Clinical Imaging*. **35** (4), 284-287 (2011).
30. Moon, S. K., *et al.* Quantification of Kidney Fibrosis Using Ultrasonic Shear Wave Elastography. *Journal of Ultrasound in Medicine*. **34**, 869-877 (2015).
31. Genovese, F., Manresa, A. A., Leeming, D. J., Karsdal, M. A., Boor, P. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? *Fibrogenesis & Tissue Repair*. **7** (1), 4 (2014).
32. Hewitson, T. D. Fibrosis in the kidney: is a problem shared a problem halved? *Fibrogenes & Tissue Repair*. **5** (1), S14 (2012).
33. Wolf, M. T., *et al.* Polypropylene surgical mesh coated with extracellular matrix mitigates the host foreign body response. *Journal of Biomedical Materials Research Part A*. **102** (1), 234–246 (2014).
34. Faulk, D. M., *et al.* ECM hydrogel coating mitigates the chronic inflammatory response to polypropylene mesh. *Biomaterials*. **35** (30), 8585–8595 (2014).
35. Jeffords, M. E., Wu, J., Shah, M., Hong, Y., Zhang, G. Tailoring Material Properties of Cardiac Matrix Hydrogels To Induce Endothelial Differentiation of Human Mesenchymal Stem


- Cells. *ACS Applied Materials & Interfaces*. **7** (20), 11053–11061 (2015).
36. Kim, M.-S., *et al.* Differential Expression of Extracellular Matrix and Adhesion Molecules in Fetal-Origin Amniotic Epithelial Cells of Preeclamptic Pregnancy. *Public Library of Science ONE*. **11** (5), e0156038 (2016).
 37. Paduano, F., Marrelli, M., White, L. J., Shakesheff, K. M., Tatullo, M. Odontogenic Differentiation of Human Dental Pulp Stem Cells on Hydrogel Scaffolds Derived from Decellularized Bone Extracellular Matrix and Collagen Type I. *Public Library of Science ONE* **11** (2), e0148225 (2016).
 38. Viswanath, A., *et al.* Extracellular matrix-derived hydrogels for dental stem cell delivery. *Journal of Biomedical Materials Research Part A*. **105** (1), 319–328 (2017).
 39. Uriel, S., *et al.* Extraction and Assembly of Tissue-Derived Gels for Cell Culture and Tissue Engineering. *Tissue Engineering Part C Methods*. **15** (3), 309–321 (2009).
 40. Saldin, L. T., Cramer, M. C., Velankar, S. S., White, L. J., Badylak, S. F. Extracellular matrix hydrogels from decellularized tissues: Structure and function. *Acta Biomaterialia*. **49**, 1–15 (2017).
 41. Faust, A., *et al.* Urinary bladder extracellular matrix hydrogels and matrix-bound vesicles differentially regulate central nervous system neuron viability and axon growth and branching. *Journal of Biomaterials Applications*. **31** (9), 1277–1295 (2017).
 42. Pouliot, R. A., *et al.* Development and characterization of a naturally derived lung extracellular matrix hydrogel. *Journal of Biomedical Materials Research Part A*. **104** (8), 1922–1935 (2016).
 43. Pati, F., *et al.* Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink. *Nature Communications*. **5**, 3935 (2014).
 44. Pati, F., *et al.* Biomimetic 3D tissue printing for soft tissue regeneration. *Biomaterials*. **62**, 164–175 (2015).
 45. Wang, R. M., Christman, K. L. Decellularized myocardial matrix hydrogels: In basic research and preclinical studies. *Advanced Drug Delivery Reviews*. **96**, 77–82 (2016).
 46. Jang, J., *et al.* 3D printed complex tissue construct using stem cell-laden decellularized extracellular matrix bioinks for cardiac repair. *Biomaterials*. **112**, 264–274 (2017).
 47. Frantz, C., Stewart, K. M., Weaver, V. M. The extracellular matrix at a glance. *Journal of Cell Science*. **123** (Pt 24), 4195–200 (2010).
 48. Mouw, J. K., Ou, G., Weaver, V. M. Extracellular matrix assembly: a multiscale deconstruction. *Nature Reviews Molecular Cell Biology*. **15** (12), 771–85 (2014).
 49. Bonnans, C., Chou, J., Werb, Z. Remodelling the extracellular matrix in development and disease. *Nature Reviews Molecular Cell Biology*. **15** (12), 786–801 (2014).
 50. Hinderer, S., Layland, S. L., Schenke-Layland, K. ECM and ECM-like materials — Biomaterials for applications in regenerative medicine and cancer therapy. *Advanced Drug Delivery Reviews*. **97**, 260–269 (2016).
 51. Uriel, S., *et al.* The role of adipose protein derived hydrogels in adipogenesis. *Biomaterials*. **29** (27), 3712–3719 (2008).
 52. Singelyn, J. M., *et al.* Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. *Biomaterials*. **30** (29), 5409–5416 (2009).
 53. Medberry, C. J., *et al.* Hydrogels derived from central nervous system extracellular matrix. *Biomaterials*. **34** (4), 1033–1040 (2013).

- 524 54. Loneker, A. E., Faulk, D. M., Hussey, G. S., D'Amore, A., Badylak, S. F. Solubilized liver
525 extracellular matrix maintains primary rat hepatocyte phenotype *in-vitro*. *Journal of*
526 *Biomedical Materials Research Part A*. **104** (4), 957–965 (2016).
- 527 55. Hill, R. C., Calle, E. A., Dzieciatkowska, M., Niklason, L. E., Hansen, K. C. Quantification of
528 extracellular matrix proteins from a rat lung scaffold to provide a molecular readout for
529 tissue engineering. *Molecular & Cellular Proteomics*. **14** (4), 961–973 (2015).
- 530 56. Li, Q., *et al.* Proteomic analysis of naturally-sourced biological scaffolds. *Biomaterials*. **75**,
531 37–46 (2016).
- 532 57. Tanaka, T., Yada, R. Y. N-terminal portion acts as an initiator of the inactivation of pepsin
533 at neutral pH. *Protein Engineering*. **14** (9), 669–674 (2001).
- 534 58. Ligresti, G., *et al.* A Novel Three-Dimensional Human Peritubular Microvascular System.
535 *Journal of the American Society of Nephrology*. **27** (8), 2370–2381 (2016).
- 536 59. Mozes, M. M., Böttinger, E. P., Jacot, T. A., Kopp, J. B. Renal expression of fibrotic matrix
537 proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta
538 transgenic mice. *Journal of the American Society of Nephrology*. **10** (2), 271–80 (1999).
- 539 60. Romanowicz, L., Galewska, Z. Extracellular matrix remodeling of the umbilical cord in pre-
540 eclampsia as a risk factor for fetal hypertension. *Journal of Pregnancy*. **2011**, 542695
541 (2011).







Click here to access/download
Video or Animated Figure
Figure 1.svg




Click here to access/download
Video or Animated Figure
Figure 2.svg





Click here to access/download
Video or Animated Figure
Figure 3.svg





Click here to access/download
Video or Animated Figure
Figure 4.svg





Click here to access/download
Video or Animated Figure
Figure 5.svg



Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Preparation of Kidney Tissue			
5000 mL Beaker	Sigma-Aldrich	Z740589	
Sodium Dodecyl Sulfate (SDS)	Sigma-Aldrich	436143	
Sterile H ₂ O			Autoclaved DI H ₂ O
Stir Bar (70 x 10 mm)	Fisher Science	14-512-128	
500 mL Vacuum Filter	VWR	97066-202	
Stir Plate	Sigma-Aldrich	CLS6795420D	
1000 mL Beaker	Sigma-Aldrich	CLS10031L	
Forceps	Sigma-Aldrich	F4642	Any similar forceps may be used
Scissor-Handle Hemostat Clamp	Sigma-Aldrich	Z168866	
Dissecting Scissors	Sigma-Aldrich	Z265977	
Scalpel Handle, No. 4	VWR	25859-000	Any similar scalpel handle may be used
Scalpel Blade, No. 20	VWR	25860-020	Any similar scalpel blade may be used
Stir Bar (38.1 x 9.5 mm)	Fisher Science	14-513-52	
Absorbent Underpad	VWR	82020-845	
Petri Dish (150 x 25 mm)	Corning	430597	
Autoclavable Biohazard Bag	VWR	14220-026	
Sterile Cell Strainer (40 um)	Fisher Science	22-363-547	
Cell Culture Grade Water	HyClone	SH30529.03	
30 mL Freestanding Tube	VWR	89012-778	
Fabrication of ECM Gel			
Tissue Homogenizer Machine	Polytron	PCU-20110	
Freeze Dryer	Labconco	7670520	
20 mL Glass Scintillation Vials and Cap	Sigma-Aldrich	V7130	
Stir Bar (15.9 x 8 mm)	Fisher Science	14-513-62	
Pepsin from Porcine Gastric Mucosa	Sigma-Aldrich	P7012	

0.01 N HCl	Sigma-Aldrich	320331	Dilute to 0.01 N HCl with cell culture water
Kidney ECM Gelation			
1 N NaOH (Sterile)	Sigma-Aldrich	415413	Dilute to 1 N in cell culture grade water
Medium 199	Sigma-Aldrich	M4530	
15 mL Conical Tube	ThermoFisher	339651	
Cell Culture Media	ThermoFisher	11330.032	Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12)
Fetal Bovine Serum (FBS)	Gibco	10082147	
Antibiotic-Antimycotic 100X	Life Technologies	15240-062	
Insulin, Transferrin, Selenium, Sodium Pyruvate Solution (ITS-A) 100X	Life Technologies	51300-044	
1 mL Syringe	Sigma-Aldrich	Z192325	
Microspatula	Sigma-Aldrich	Z193208	



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Fabricating a Kidney Extracellular Matrix-Derived Hydrogel

Author(s):

Hiraki, Harrison; Nagao, Ryan; Zheng, Ying; Himmelfarb, Johnathan

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):



The Author is NOT a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Ying Zheng		
Department:	Department of Bioengineering		
Institution:	University of Washington		
Article Title:	Fabricating a Kidney Extracellular Matrix-Derived Hydrogel		
Signature:		Date:	4/1/2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Vineeta Bajaj
Review Editor
Journal of Visualized Experiments

July 17, 2018

Subject: Revision and Resubmission of manuscript JoVE58314

Dear Dr. Bajaj,

Thank you for your email dated July 10, 2018, containing editor comments and the opportunity to revise our paper on 'Fabricating a Kidney Cortex Extracellular Matrix-Derived Hydrogel'. We appreciate your helpful comments in the protocol section. Editor comments are included below, immediately followed by responses indicating how we addressed each comment. Changes to the manuscript are shown in red.

The manuscript has been thoroughly proofread and spelling and grammatical corrections have been made. Correct reference for use of previously published figures have been added to figure captions 2, 3, and 5 and explicit reprint permission has been obtained. The revisions prompted by the editor's comments are minor and require no further explanation beyond what appears in our responses below.

We hope the manuscript will suit the *Journal of Visualized Experiments*, but are happy to consider further revisions. We thank you for your continued interest in our research.

Sincerely,

Ying Zheng
Associate Professor
Department of Bioengineering
University of Washington

Editor Comments and Author Responses, and Manuscript Changes

1. *Line 26, Please expand during first time use.*

Response: Thank you for pointing out a lack of proper definition here. ECM has been initially defined on line 26 and subsequent repetitive defining of ECM was removed on line 35.

2. *Line 54, This is commercial. Please use generic term instead. Maybe non-ionic detergent? The commercial term can be sufficiently referenced in the table of materials.*

Response: We appreciate you catching this mistake. On line 55, we have used non-ionic detergent and included the catalogue number for the Triton-X100 used in the materials table.

3. *Line 108, Please include a note stating where is the kidney obtained from? Is it fresh or frozen and other necessary details.*

Response: Thank you for addressing that a clarification is needed at this point in the protocol. We have included a note on line 109 stating where the kidney was obtained from and its condition.

4. *Line 116, How? using what?*

Response: Thank you for your comment to improve the clarity of the protocol. In lines 119-120 we state that a scalpel should be used and describe how the kidney should be bisected.

5. *Line 117, Using what?*

Response: Thank you again for your insight into how to improve the clarity of the protocol. In lines 120-121 we have stated that a scalpel was used to perform this step.

6. *Line 124, Aluminum foil?*

Response: We appreciate your comment. We have changed the use of tinfoil to aluminum foil on lines 102, 128, and 142.

7. *Line 128, Also transwell is a commercial term. Please use generic term and refer to the commercial term in the table of materials.*

Response: We appreciate you pointing out the use of a commercial term throughout the protocol section. We have changed transwell to nylon mesh cell strainer on lines 132, 135, 136, 139, and 141.

8. *Lines 131-132, How much? Are you pipetting out or in?*

Response: Thank you for your clarifying comment. On line 135 we added that the SDS solution should be pipetted out of the beaker and that all of the SDS solution in the beaker should be removed.

9. *Lines 132-133, Please make this a note or convert to imperative tense.*

Response: We appreciate your insight. We have made the explanation of the cell strainer a note on line 139.

10. *Lines 141-145, To be done after 5 days wash with SDS? ,So the washes goes for 10 days?*

Response: Thank you for pointing out a potentially confusing part of the protocol. We have reworded steps 1.3.5 and 1.3.6 on lines 146-150 to better explain the work done.

11. *Lines 155-156, This is done in the conical tube?*

Response: We appreciate you bringing up this part of the protocol that is not well defined. We have reworded step 2.1.1 on lines 160-161 to explain that the homogenization of the ECM should take place within the conical tube.

12. *Line 158, Converted to a note since not in imperative tense. Also, removed the highlight since notes cannot be filmed.*

Response: We appreciate your edit that made the protocol section more consistent with the use of notes!

13. *Lines 174-176, Calculation steps cannot be filmed, so highlights removed.*

Response: Thank you for your comment. We have removed highlights on all steps within the protocol that are only calculations.

14. *Lines 193-194, What volume and concentration was used?*

Response: We appreciate your comment and agree that the information should be included in the protocol. We have added to the note on lines 199-200 explaining what volume and concentration of kECM gel was needed to perform the experiments outlined in the results section.

15. *Lines 198-200, Please use imperative tense.*

Response: Thank you for pointing out this flaw in our protocol section. We have made corrections to the wording within the protocol section to remove any text that is not in imperative tense.

16. *Lines 218-223, Please make substeps as we cannot have paragraphs of text in the protocol section.*

Response: We appreciate your comment to improve the protocol section. We have split step 3.1.2 into multiple substeps and a note in lines 219-227.

17. *Lines 225-227, How many cells and how much culture media?*

Response: We appreciate your comment and agree that this is necessary information to add. We have better outlined how much cell culture media and cells are needed to incorporate in the gel in step 3.1.1.6 and substeps in lines 229-242.



Harrison Hiraki <hirakih@gmail.com>

Request to Permission to Adapt Figures

Ballen, Karen <KBallen@liebertpub.com>
To: Harrison Hiraki <hirakih@uw.edu>

Thu, Jul 12, 2018 at 12:34 PM

Dear Harrison:

Copyright permission is granted for your request to use and adapt figures from Dr. Nagao's article in TISSUE ENGINEERING, Part A, Volume 22, Issues 19 & 20, pp. 1140-1150.

Please give credit to Mary Ann Liebert, Inc., publishers; New Rochelle, NY.

Kind regards,

Karen Ballen

Manager, Reprints, Permissions, and Open Access

From: Harrison Hiraki <hirakih@uw.edu>
Sent: Thursday, July 12, 2018 1:19 PM
To: Ballen, Karen <KBallen@liebertpub.com>
Subject: Re: Request to Permission to Adapt Figures

[Quoted text hidden]